Literature DB >> 2331992

Fate of interleukin-6 in the rat. Involvement of skin in its catabolism.

J Castell1, J Klapproth, V Gross, E Walter, T Andus, L Snyers, J Content, P C Heinrich.   

Abstract

Iodinated recombinant human interleukin-6 (125I-rhIL-6) was intravenously injected into rats and its fate was studied during 24 h. Between 10-20 min after a single-dose injection, 125I-rhIL-6 accumulated in liver as previously reported [Castell et al. (1988) Eur. J. Biochem. 177, 357-361]. After 1 h, the radioactivity disappeared from the liver and accumulated in skin, reaching 35% of injected 125I-rhIL-6 5-8 h after injection. No comparable accumulation of radioactivity was found in skin when [125I]iodide or rat serum 125I-albumin was administered. Finally the radioactivity was detected as [125I]iodide in urine. Autoradiographic analysis of skin sections 5 h after 125I-rhIL-6 injection showed radioactivity in the interstitium. When the experiments were carried out with [35S]rhIL-6, essentially the same results were obtained: a decrease in radioactivity in the liver after 20 min, and a substantial increase in skin 7 h after injection. In vitro experiments showed that 125I-rhIL-6 is degraded by rat and human fibroblasts, whereas no degradation was observed with rat hepatoma cells (Fao) or human hepatocytes. These observations suggest the involvement of skin in the catabolism of IL-6.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2331992     DOI: 10.1111/j.1432-1033.1990.tb15466.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

Review 1.  Interleukin 6 and liver regeneration.

Authors:  K L Streetz; T Luedde; M P Manns; C Trautwein
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

2.  Selective and early increase of IL-1 inhibitors, IL-6 and cortisol after elective surgery.

Authors:  F Di Padova; C Pozzi; M J Tondre; R Tritapepe
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

3.  A multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6 (PEG-rhIL-6) in rats.

Authors:  Xue-ling He; Hai-lin Yin; Jiang Wu; Ke Zhang; Yan Liu; Tao Yuan; Hai-lin Rao; Liang Li; Guang Yang; Xue-mei Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2011-01       Impact factor: 3.066

Review 4.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

5.  Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.

Authors:  H C van Zaanen; R P Koopmans; L A Aarden; H J Rensink; J M Stouthard; S O Warnaar; H M Lokhorst; M H van Oers
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

6.  Interleukin-6 in psoriasis: expression and mitogenicity studies.

Authors:  J T Elder; C I Sartor; D K Boman; S Benrazavi; G J Fisher; M R Pittelkow
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

7.  Liver Failure Impairs the Intrahepatic Elimination of Interleukin-6, Tumor Necrosis Factor-Alpha, Hepatocyte Growth Factor, and Transforming Growth Factor-Beta.

Authors:  Dawid Porowski; Agnieszka Wirkowska; Ewa Hryniewiecka; Janusz Wyzgał; Marek Pacholczyk; Leszek Pączek
Journal:  Biomed Res Int       Date:  2015-05-21       Impact factor: 3.411

8.  Interleukin-6 secretion is limited by self-signaling in endosomes.

Authors:  Daniëlle R J Verboogen; Natalia H Revelo; Martin Ter Beest; Geert van den Bogaart
Journal:  J Mol Cell Biol       Date:  2019-02-01       Impact factor: 6.216

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.